Open AccessTotal Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer
Author(s) -
Janet E. Murphy,
Jennifer Y. Wo,
David P. Ryan,
Jeffrey W. Clark,
Wenqing Jiang,
Beow Y. Yeap,
Lorraine C. Drapek,
Leilana Ly,
Christian V. Baglini,
Lawrence S. Blaszkowsky,
Cristina R. Ferrone,
Aparna R. Parikh,
Colin D. Weekes,
Ryan David Nipp,
Eunice L. Kwak,
Jill N. Allen,
Ryan B. Corcoran,
David T. Ting,
Jason E. Faris,
Andrew X. Zhu,
Lipika Goyal,
David L. Berger,
Motaz Qadan,
Keith D. Lillemoe,
Nilesh P. Talele,
Rakesh K. Jain,
Thomas F. DeLaney,
Dan G. Duda,
Yves Boucher,
Carlos Fernández-del Castillo,
Theodore S. Hong
Publication year - 2019
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2019.0892
Subject(s) - medicine , folfirinox , capecitabine , chemoradiotherapy , irinotecan , oxaliplatin , pancreatic cancer , neoadjuvant therapy , oncology , surgery , cancer , colorectal cancer , breast cancer
Patients with locally advanced pancreatic cancer have historically poor outcomes. Evaluation of a total neoadjuvant approach is warranted.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom